Illumina, Inc. (ILMN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 3,239 | 4,526 | 4,584 | 4,504 | 4,372 | 4,338 | 4,493 | 4,624 |
| Operating profit | $m | 864 | 942 | ||||||
| Net profit | $m | 656 | 762 | -4,404 | -1,161 | -1,223 | 850 | 825 | 837 |
| EPS reported | $ | 5.45 | 5.36 | ||||||
| Operating cashflow per share | $ | 6.96 | 7.25 | ||||||
| Capex per share | $ | 0.95 | 1.03 | ||||||
| FCF per share | $ | 6.01 | 6.22 | ||||||
| Free cash flow | $m | 931 | 939 | ||||||
| Net debt | $m | 356 | 905 | ||||||
| Book value equity | $m | 2,723 | 2,838 | ||||||
| Book value per share | $ | 17.46 | 18.55 | ||||||
| Number of shares | m | 156 | 153 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 24.76 | 50.37 | ||||||
| P/B LTM | x | 7.65 | 7.34 | ||||||
| P/S LTM | x | 4.81 | 4.64 | ||||||
| P/FCF LTM | x | 22.39 | 22.20 | ||||||
| EV/EBITDA LTM | x | 15.09 | 16.13 | ||||||
| EV/Sales LTM | x | 5.07 | 6.76 | ||||||
| Earnings Yield LTM | % | +4.04% | +1.99% | ||||||
| FCF Yield | % | +4.47% | +4.50% | ||||||
| Quality | |||||||||
| ROE | % | +31.22% | +31.08% | ||||||
| ROIC | % | +12.00% | +13.54% | ||||||
| Operating margin | % | +19.92% | +20.97% | ||||||
| Gross margin | % | +66.69% | +66.79% | ||||||
| FCF/Sales | % | +21.46% | +20.90% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -0.78% | +2.77% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +31.31% | +32.44% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.36 | 0.37 | ||||||
| Net Debt/EBITDA | x | 0.78 | 1.09 | ||||||
| EBIT/Net interest | x | 8.55 | 12.56 | ||||||
| Net debt/market cap | % | +9.54% | +6.89% | ||||||
| Net debt/Equity | x | 0.13 | 0.32 | ||||||
| Gross debt/equity | x | 0.94 | 0.89 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free